Project Number 5P50AG025711-05 Agency/Funding Organization NIA Funding Year 2009 View Full Project Details for COGNITIVE REHABILITATION IN ALZHEIMER'S DISEASE Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 9. Non-Pharmacological Interventions c. Cognitive Training Category F. Research Resources 1. Alzheimer's Disease Centers Researcher and Organization Principal Investigator LOEWENSTEIN, DAVID Principal Investigator First Name DAVID Principal Investigator Last Name LOEWENSTEIN Awardee Organization UNIVERSITY OF SOUTH FLORIDA Awardee State Florida Contact PI Country United States Project Detail Funding Opportunity Announcement RFA-AG-04-011: ALZHEIMER’S DISEASE RESEARCH CENTERS FY Overall Cost $135,755 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official PHELPS, CREIGHTON H. Related Resources Repository [NIAGADS] Mayo GWAS [AlzPED] Adeno-Associated Viral Vector Mediated Gene Delivery of Endothelin Converting Enzyme Reduces Aβ Deposits in APP +PS-1 Transgenic Mice [AlzPED] Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. [AlzPED] A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. [AlzPED] Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. [AlzPED] Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid β, Amyloid β40, and Amyloid β42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice [AlzPED] Aβ vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid.